JP2022547081A5 - - Google Patents

Info

Publication number
JP2022547081A5
JP2022547081A5 JP2022514681A JP2022514681A JP2022547081A5 JP 2022547081 A5 JP2022547081 A5 JP 2022547081A5 JP 2022514681 A JP2022514681 A JP 2022514681A JP 2022514681 A JP2022514681 A JP 2022514681A JP 2022547081 A5 JP2022547081 A5 JP 2022547081A5
Authority
JP
Japan
Application number
JP2022514681A
Other languages
Japanese (ja)
Other versions
JP2022547081A (ja
JP7662617B2 (ja
JPWO2021044005A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/074804 external-priority patent/WO2021044005A1/en
Publication of JP2022547081A publication Critical patent/JP2022547081A/ja
Publication of JP2022547081A5 publication Critical patent/JP2022547081A5/ja
Publication of JPWO2021044005A5 publication Critical patent/JPWO2021044005A5/ja
Application granted granted Critical
Publication of JP7662617B2 publication Critical patent/JP7662617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514681A 2019-09-06 2020-09-04 抗cd73抗体 Active JP7662617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896908P 2019-09-06 2019-09-06
US62/896,908 2019-09-06
PCT/EP2020/074804 WO2021044005A1 (en) 2019-09-06 2020-09-04 Anti-cd73 antibodies

Publications (4)

Publication Number Publication Date
JP2022547081A JP2022547081A (ja) 2022-11-10
JP2022547081A5 true JP2022547081A5 (https=) 2023-09-08
JPWO2021044005A5 JPWO2021044005A5 (https=) 2023-09-08
JP7662617B2 JP7662617B2 (ja) 2025-04-15

Family

ID=72517218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514681A Active JP7662617B2 (ja) 2019-09-06 2020-09-04 抗cd73抗体

Country Status (18)

Country Link
US (2) US11634500B2 (https=)
EP (1) EP4025605A1 (https=)
JP (1) JP7662617B2 (https=)
KR (1) KR20220057558A (https=)
CN (1) CN115023439B (https=)
AU (1) AU2020342778A1 (https=)
BR (1) BR112022003956A2 (https=)
CA (1) CA3153213A1 (https=)
CL (1) CL2024002093A1 (https=)
CO (1) CO2022002622A2 (https=)
IL (1) IL291068A (https=)
MX (1) MX2022002682A (https=)
MY (1) MY207784A (https=)
PE (1) PE20220708A1 (https=)
PH (1) PH12022550509A1 (https=)
TW (1) TWI859319B (https=)
UA (1) UA130408C2 (https=)
WO (1) WO2021044005A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
CA3166536A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CN115734972A (zh) * 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US338841A (en) 1886-03-30 herden
US256055A (en) 1882-04-04 Compound engine
US323997A (en) 1885-08-11 Machine-gun
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
AU5914201A (en) 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
WO2006113181A2 (en) 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
BRPI0612947A2 (pt) 2005-05-18 2010-12-07 Biogen Idec Inc método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
US20130331297A1 (en) * 2010-07-16 2013-12-12 Avantgen, Inc. Novel peptides and uses thereof
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US10059761B2 (en) * 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
IL250579B2 (en) 2014-10-10 2023-05-01 Innate Pharma blocking cd73
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
DK3218406T4 (da) 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
EP3218407A1 (en) 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
CA2988119A1 (en) 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
WO2017167921A1 (en) 2016-03-30 2017-10-05 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
MY194596A (en) * 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
MY203971A (en) * 2016-10-13 2024-07-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法

Similar Documents

Publication Publication Date Title
CN305530921S (https=)
CN305670797S (https=)
CN305531664S (https=)
CN305546449S (https=)
CN305546793S (https=)
CN305547376S (https=)
CN305550355S (https=)
CN305551009S (https=)
CN305551537S (https=)
CN305552091S (https=)
CN305554952S (https=)
CN305556860S (https=)
CN305558319S (https=)
CN305559938S (https=)
CN305574520S (https=)
CN305609507S (https=)
CN305631112S (https=)
CN305647066S (https=)
CN305648599S (https=)
CN305649835S (https=)
CN305653769S (https=)
CN305658538S (https=)
CN305660034S (https=)
CN305662874S (https=)
CN305663135S (https=)